New Companies

Found 4,162 articles

• TAAV launches new corporate brand as a reflection of its transformation

  5/2/2023

  TAAV Biomanufacturing Solutions S.L.U. presents a new brand that supports the company's transformation and purpose, which is to be the DNA manufacturing partner of choice for developers of recombinant adeno-associate virus technologies and thus become a fundamental part of the gene therapy industry.

• Therapeutic Solutions International Launches VasoSome Vascular Inc Based on Successful Treatment of Aortic Aneurysms using Patent Pending Exosome Therapy

  5/1/2023

  Therapeutic Solutions International (TSOI) announced formation of a new spin-off company, VasoSome Vascular Inc, focused on treating the “living timebomb” condition of aortic aneurysms using stem cell derived exosomes.

• Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis

  4/25/2023

  Pan-Biome Pharmaceuticals, Inc, is pleased to announce that its lead compound exhibited protective effects in a preclinical model of inflammatory colitis. 

• 

  Abdera Debuts with $142M to Develop Precision Radiopharmaceuticals

  4/20/2023

  Abdera Therapeutics will use the money to fund its ROVEr platform and advance its lead asset ABD-147 for small-cell lung cancer.
• 

  Aer Therapeutics Raises $36M for Novel Approach to COPD

  4/14/2023

  Aer’s inhaled formulation targets the mucus plugs obstructing COPD patients’ airways.
• 

  Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1

  3/29/2023

  Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.

• Biotechnology Veteran Dr. Thomas Ichim to Lead Suicide Prediction Company Campbell Neurosciences, Inc.

  3/27/2023

  Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced today the appointment of Thomas Ichim, Ph.D., as President, and Chief Executive Officer of Campbell Neurosciences.

• Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

  3/21/2023

  Enveric Biosciences today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.

• 

  Seamless Launches with $12.5M for Programmable Recombinases Platform

  3/16/2023

  Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing.
• 

  Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift

  3/15/2023

  Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.
• 

  Amplifier Launches to Bring First AMPK Activator to the Clinic

  3/14/2023

  Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.
• 

  Closing the Opportunity Gap: How Inceptor Bio Supports Women Leaders

  3/9/2023

  Women are often at the forefront of innovation, making up nearly half of the life sciences industry despite a shrinking but persistent wage gap. Inceptor Bio is at the forefront of closing inequality.

• Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

  3/6/2023

  Starlight Therapeutics Inc., a Lantern subsidiary, will focus exclusively on the clinical development of therapies for CNS (central nervous system) and brain cancers with limited or no effective therapeutic options.

• Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease

  3/6/2023

  Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.

• 

  George Church-Backed Thymmune Launches to Target Overlooked Organ

  3/2/2023

  Thymmune is backed by an A-list team of investors including Pillar VC, former Alnylam CEO John Maraganore and famed geneticist George Church.

• Zymtronix Welcomes Thomas Videbaek to Its Board of Directors

  2/28/2023

  Zymtronix, Inc., a groundbreaking new biotechnology company, today announced that Dr. Thomas Videbaek, biotech industry veteran and former Executive Vice President (EVP) of Novozymes, is joining its Board of Directors.

• 

  Alnylam Vets Raise $193M to Solve Gene Therapy's Biggest Hurdle - Delivery

  2/16/2023

  Aera Therapeutics emerged from stealth mode Thursday with a platform based on the work of Feng Zhang, Ph.D. and ex-Alnylam executive Akin Akinc at the helm.
• 

  Alexis Borisy and Co. Raise $520M for New Model VC

  2/15/2023

  Curie.Bio launched this week with $520 million to take early startups from ground zero through Series A funding.
• 

  AstraZeneca Spin-off Aristea Folds After Safety Issues End Lead Program

  2/13/2023

  Due to safety concerns, Aristea Therapeutics announced Friday that it was discontinuing the development of its Phase II lead program. As a result, the San Diego-based biotech is also dissolving its business.

• FibroBiologics Sets Record as Fastest Rising Biotech in History with StartEngine.com

  2/1/2023

  FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, announced they are the fastest rising biotech offering in StartEngine's history surpassing $1 million of new investments on the first day of its Reg CF offering.